Invitation to attend SMI's 8th annual...
Adaptive Designs in Clinical Trials
18-19 APRIL 2016, Holiday Inn Regents Park, London, UK
WE ARE DELIGHTED TO PROVIDE A SPECIAL OFFER FOR PSI SUBSCRIBERS!
QUOTE SMIMLHN WHEN BOOKING ONLINE AND SAVE £100!*
WHY YOU CAN'T MISS
ADAPTIVE DESIGNS IN CLINICAL TRIALS 2016
Who
will you meet?
Build future collaborations by networking with industry professionals from:
Affibody, AstraZeneca, Bays Consulting, Boehringer-Ingelheim, Cancer Research UK, Cornell University, Debiopharm International, EMD Serono, Enterome, European Medicines Agency (EMA), hVIVO, INSERM, Lundbeck A/S, MHRA, Orion Pharma, Pfizer Global Pharmaceuticals, Queen Mary, University of London, Rottapharm Biotech, Sanofi Aventis, Synthon BV, The Cure Parkinsons Trust, University of Pisa, University of Sheffield, Warwick Medical School and many more...
Event Highlights:
Adaptive designs offer the potential to reduce timelines and patient exposure while maximising the probability for successful outcomes. However, along with these benefits come challenges: additional complexity, needs for advanced statistical models and increased operational demands.
The conference will highlight an array of topics including adaptive designs within the context of a development programme, Bayesian analysis in adaptive design, biomarker-driven trials, regulatory issues associated with adaptive design, and more.
Key presentations include:
- Bo Huang, Director of Biostatistics, Pfizer will present opportunities of adaptive enrichment designs in the area of precision medicine.
- Olivier Collignon Statistics consultant, European Medicines Agency (EMA) will be speaking on adaptive designs in clinical trials from scientific advice to marketing authorisation: lessons learnt from submissions to the European Medicine Agency
- Panel discussion: The role of biomarker-driven adaptive designs in clinical development from Loïc Darchy, Head of Statistical Methodology Group, Sanofi R&D
- Philip Hougaard, Vice President, Biometrics, Lundbeck A/S will be presenting on adaptive designs in proof-of-concept studies (Phase IIa) and dose-finding studies (Phase IIb)
HOW TO GET INVOLVED?
For sponsorship information: Contact Andrew Gibbons on +44(0) 207 827 6156 or agibbons@smi-online.co.uk
For delegate registrations: Contact Matthew Apps on +44(0) 207 827 6093 or mapps@smi-online.co.uk